June 18, 2026
StemRIM Inc.

Notice Regarding Recognition of Non-operating Income (Subsidy Income)

Osaka, Japan, June 18, 2026 – StemRIM Inc. (TSE:4599, President and CEO: Masatsune Okajima; "StemRIM" or "Company") announces that it will record non-operating income (subsidy income) in the fourth quarter of the fiscal year ending July 31, 2026 (May 1, 2026 to July 31, 2026), as described below.

1. Details of Non-operating Income (Subsidy Income)

The Company has been selected for the “FY2024 Project for Development of Fundamental Technologies for Industrialization of Regenerative Medicine and Gene Therapy (Project for Promotion of Industrialization of Regenerative Medicine, Cell Therapy, and Gene Therapy)” conducted by the Japan Agency for Medical Research and Development (AMED), and is currently engaged in the project titled “Development of Curative Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa.”

We are pleased to announce that the receipt of a subsidy for FY2025 (April 1, 2025 to March 31, 2026) related to this project has been finalized. Accordingly, the Company will record 59,973 thousand yen as subsidy income under non-operating income for the current period.

Under this project, up to two-thirds of eligible expenses may be covered by the AMED subsidy, and the Company is eligible to receive a maximum of 179 million yen in subsidies for the period from FY2024 to FY2026 (April 1, 2024 to March 31, 2027). For the fiscal year ending July 31, 2026, the receipt of subsidies for FY2024 (12,133 thousand yen) and FY2025 (59,973 thousand yen) has been finalized and recorded as non-operating income.

This research is based on stem cell gene therapy (development code: SR-GT1), which the Company is developing in collaboration with the Graduate School of Medicine, Osaka University. It utilizes proprietary technology as a platform to minimally invasively harvest mesenchymal stem cells from patients’ skin. A lentiviral vector is then used to efficiently introduce the type VII collagen gene into patient-derived mesenchymal stem cells, which are subsequently transplanted back into the patient’s skin to enable sustained production of type VII collagen, aiming to establish a curative treatment for epidermolysis bullosa.

A key feature of this technology is the use of autologous cells, which is expected to provide long-term therapeutic effects. As there is currently no curative treatment for recessive dystrophic epidermolysis bullosa, this approach is anticipated to offer a new therapeutic option.

Recessive dystrophic epidermolysis bullosa is a designated intractable disease in Japan caused by a genetic deficiency of type VII collagen, which is essential for adhesion in the epidermis. Patients suffer from recurrent severe blistering, erosion, and ulceration across the body from birth. Over time, progressive scarring (fibrosis) leads to complications such

as fusion of fingers, restricted mouth opening, and esophageal stenosis, significantly impairing quality of life (QOL). The development of a curative treatment remains an urgent medical challenge.

In this research, the Company will build upon the cell-processing manufacturing system established in AMED Step 1 and incorporate guidance received through consultations with the Pharmaceuticals and Medical Devices Agency (PMDA). The goal is to manufacture investigational products with a view toward clinical application and to promptly transition to an investigator-initiated clinical trial.

2. Impact on Financial Results

The subsidy described above, for which receipt has been finalized, is expected to be recorded as non-operating income in the fourth quarter of the fiscal year ending July 31, 2026.

Notes:

1. Scarring (Fibrosis): The process by which damaged tissue is repaired and replaced with scar tissue; while essential for healing, excessive scarring may lead to functional impairment.

2. Lentiviral Vector: A type of viral vector derived from lentiviruses (e.g., HIV-1), widely used in gene therapy and regenerative medicine for efficient and long-term gene delivery, including in non-dividing cells.

Inquiries:

StemRIM Inc.
Management & Administrator Dept.
E-Mail: stemrim-ir@stemrim.com
X: @StemRIM_Inc

For more information, please visit the StemRIM website (https://stemrim.com/english/)